ICU Medical, Inc. Announces Executive changes, Effective March 18, 2022
February 18, 2022 at 08:58 am EST
Share
ICU Medical, Inc. announced that On February 16, 2022, Kevin McGrody, age 63, informed the Company of his intention to retire as Chief Accounting Officer of the Company effective March 18, 2022. The Company has commenced a search for his successor. From the date of Mr. McGrody's retirement until a new Chief Accounting Officer is appointed, Brian Bonnell, the Company's Chief Financial Officer, will assume Mr. McGrody's responsibilities.
ICU Medical, Inc. develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications. Its product portfolio includes ambulatory, syringe, and large volume IV pumps and safety software; dedicated and non-dedicated IV sets, needle free IV connectors, peripheral IV catheters, and sterile IV solutions; closed system transfer devices and pharmacy compounding systems; as well as a range of respiratory, anesthesia, patient monitoring, and temperature management products. Its Infusion Therapy products include Clave needlefree products, Neutron, and Tego. Its oncology products include ChemoLock Closed System Transfer Devices (CSTD) and Deltec GRIPPER non-coring needles for portal access. Its vascular access products include Safe-T Wing venipuncture and blood collection devices; Port-A-Cath implantable port, and Portex arterial blood sampling syringes. Its Tracheostomy product include Portex BLUselect PVC tracheostomy tubes.
ICU MEDICAL, INC. 
